Zhejiang Orient Gene Biotech saw the highest growth of 74% in patent filings and 99% in grants in November in Q4 2023. Compared to Q3 2023, Q4 2023 saw an increase in patent filings by 39% and grants by 66%. GlobalData’s DataBook provides a comprehensive analysis of Zhejiang Orient Gene Biotech’s patent filings and grants. Buy the databook here.
Zhejiang Orient Gene Biotech has been focused on protecting inventions in United States(US) with five publications in Q4 2023
The United States(US) Patent Office dominates the patent filings and grants with nearly 14% filings and 100% grants. The Australia(AU), China(CN), United States(US), and European Patent Office(EPO) patent Office are among the top ten patent offices where Zhejiang Orient Gene Biotech is filings its patents. Among the top granted patent authorities, Zhejiang Orient Gene Biotech has 100% of its grants in United States(US)
In terms of grant share, Zhejiang Orient Gene Biotech stands in ninth position among its competitors. and secured the top positions according to recent patent publication data.
See Also:
Patents related to industrial automation and climate change lead Zhejiang Orient Gene Biotech's portfolio
Zhejiang Orient Gene Biotech has the highest number of patents in industrial automation followed by, climate change and rare diseases. For industrial automation, nearly 57% of patents were filed and 100% of patents were granted in Q4 2023.
For comprehensive analysis of Zhejiang Orient Gene Biotech's filings and grants, buy the databook here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.